Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies

NCT01061749 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

NIH

Sponsor class

Conditions

Adult Solid Neoplasm

Interventions

BIOLOGICAL: Cixutumumab
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Selumetinib

Sponsor

National Cancer Institute (NCI)